EBRO 2017

RT versus concomitant CTRT

• Trials

• 12 eligible (1921 patients) • 9 included (1764 patients, 1657 deaths) • Overall survival • HR = 0.89 [0.81 – 0.98] • +4% @ 2 years, +2.2% @ 5 years • NTT : 25 @ 2 years, 45 @ 5 years • Event free survival • HR = 0.84 [0.74 – 0.96] • +6% @ 2 years, +3.5% @ 5 years

Auperin Ann Oncol 2006